Tranexamic Acid and Plasminogen/Plasmin Glaring Paradox in COVID-19.
Endocr Metab Immune Disord Drug Targets
; 2022 Aug 01.
Article
in English
| MEDLINE | ID: covidwho-2238464
ABSTRACT
Coronavirus disease 2019 (COVID-19) is caused by a severe acute respiratory distress syndrome, coronavirus type 2 (SARS-CoV-2), leading to acute tissue injury and an overstated immune response. In COVID-19, there are noteworthy changes in the fibrinolytic system with the development of coagulopathy. Therefore, modulation of the fibrinolytic system may affect the course of COVID-19. Tranexamic acid (TXA) is an anti-fibrinolytic drug that reduces the conversion of plasminogen to plasmin, which is necessary for SARS-CoV-2 infectivity. In addition, TXA has anti-inflammatory, anti-platelet, and anti-thrombotic effects, which may attenuate the COVID-19 severity. Thus, in this narrative review, we try to find the beneficial and harmful effects of TXA in COVID-19.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Prognostic study
/
Reviews
Language:
English
Journal subject:
Allergy and Immunology
/
Endocrinology
/
Metabolism
/
Drug Therapy
Year:
2022
Document Type:
Article
Affiliation country:
1871530322666220801102402
Similar
MEDLINE
...
LILACS
LIS